HDAC6 and amyotrophic lateral sclerosis: Furthermore, defects caused by FUS or TDP-43 mutations have recently suggested to be regulated by HDAC6 inhibition [77, 78], indicating that HDAC6 may be a valuable target for ALS treatment.